$1.33 Billion is the total value of Ikarian Capital, LLC's 151 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ALPN | Exit | ALPINE IMMUNE SCIENCES INC | $0 | – | -4,739 | -100.0% | -0.00% | – |
| BHVN | Exit | BIOHAVEN PHARMACTL HLDG CO L | $0 | – | -642 | -100.0% | -0.01% | – |
| CARA | Exit | CARA THERAPEUTICS INCput | $0 | – | -4,200 | -100.0% | -0.01% | – |
| PIRS | Exit | PIERIS PHARMACEUTICALS INCcall | $0 | – | -22,000 | -100.0% | -0.01% | – |
| NVAX | Exit | NOVAVAX INC | $0 | – | -25,049 | -100.0% | -0.02% | – |
| XFOR | Exit | X4 PHARMACEUTICALS INC | $0 | – | -10,000 | -100.0% | -0.02% | – |
| ARVN | Exit | ARVINAS INCput | $0 | – | -3,100 | -100.0% | -0.02% | – |
| MGTA | Exit | MAGENTA THERAPEUTICS INC | $0 | – | -8,674 | -100.0% | -0.02% | – |
| SRRA | Exit | SIERRA ONCOLOGY INC | $0 | – | -386,399 | -100.0% | -0.02% | – |
| PRTO | Exit | PROTEON THERAPEUTICS INC | $0 | – | -336,373 | -100.0% | -0.02% | – |
| PRTA | Exit | PROTHENA CORP PLC | $0 | – | -29,832 | -100.0% | -0.08% | – |
| MTEM | Exit | MOLECULAR TEMPLATES INC | $0 | – | -40,907 | -100.0% | -0.09% | – |
| OCUL | Exit | OCULAR THERAPEUTIX INCcall | $0 | – | -150,000 | -100.0% | -0.10% | – |
| WVE | Exit | WAVE LIFE SCIENCES LTDcall | $0 | – | -134,400 | -100.0% | -0.18% | – |
| DTIL | Exit | PRECISION BIOSCIENCES INC | $0 | – | -80,000 | -100.0% | -0.18% | – |
| PBYI | Exit | PUMA BIOTECHNOLOGY INCcall | $0 | – | -132,700 | -100.0% | -0.19% | – |
| VKTX | Exit | VIKING THERAPEUTICS INCcall | $0 | – | -150,000 | -100.0% | -0.20% | – |
| VKTX | Exit | VIKING THERAPEUTICS INCput | $0 | – | -150,000 | -100.0% | -0.20% | – |
| AIMT | Exit | AIMMUNE THERAPEUTICS INC | $0 | – | -40,000 | -100.0% | -0.22% | – |
| KALA | Exit | KALA PHARMACEUTICALS INCcall | $0 | – | -395,500 | -100.0% | -0.24% | – |
| MGNX | Exit | MACROGENICS INCcall | $0 | – | -150,000 | -100.0% | -0.26% | – |
| CCXI | Exit | CHEMOCENTRYX INC | $0 | – | -46,423 | -100.0% | -0.30% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -143,000 | -100.0% | -0.38% | – |
| AGIO | Exit | AGIOS PHARMACEUTICALS INCcall | $0 | – | -50,000 | -100.0% | -0.39% | – |
| WVE | Exit | WAVE LIFE SCIENCES LTDput | $0 | – | -300,000 | -100.0% | -0.39% | – |
| ARQL | Exit | ARQULE INC | $0 | – | -148,930 | -100.0% | -0.48% | – |
| ANAB | Exit | ANAPTYSBIO INCput | $0 | – | -193,300 | -100.0% | -0.51% | – |
| TGTX | Exit | TG THERAPEUTICS INC | $0 | – | -316,200 | -100.0% | -0.57% | – |
| Exit | APTOSE BIOSCIENCES INC | $0 | – | -1,009,735 | -100.0% | -0.93% | – | |
| EIDX | Exit | EIDOS THERAPEUTICS INCcall | $0 | – | -100,000 | -100.0% | -0.93% | – |
| DCPH | Exit | DECIPHERA PHARMACEUTICALS INcall | $0 | – | -100,000 | -100.0% | -1.01% | – |
| ARWR | Exit | ARROWHEAD PHARMACEUTICALS INcall | $0 | – | -100,000 | -100.0% | -1.03% | – |
| ARQL | Exit | ARQULE INCput | $0 | – | -336,400 | -100.0% | -1.09% | – |
| INCY | Exit | INCYTE CORPcall | $0 | – | -80,000 | -100.0% | -1.13% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INCcall | $0 | – | -240,300 | -100.0% | -1.19% | – |
| APLS | Exit | APELLIS PHARMACEUTICALS INCput | $0 | – | -286,900 | -100.0% | -1.42% | – |
| MDGL | Exit | MADRIGAL PHARMACEUTICALS INCput | $0 | – | -100,000 | -100.0% | -1.48% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INCcall | $0 | – | -267,100 | -100.0% | -1.48% | – |
| ASND | Exit | ASCENDIS PHARMA A Scall | $0 | – | -69,400 | -100.0% | -1.56% | – |
| ARQL | Exit | ARQULE INCcall | $0 | – | -497,700 | -100.0% | -1.61% | – |
| GWPH | Exit | GW PHARMACEUTICALS PLCcall | $0 | – | -100,000 | -100.0% | -1.69% | – |
| GOSS | Exit | GOSSAMER BIO INCput | $0 | – | -771,100 | -100.0% | -1.95% | – |
| BGNE | Exit | BEIGENE LTDput | $0 | – | -77,000 | -100.0% | -2.07% | – |
| MRTX | Exit | MIRATI THERAPEUTICS INCcall | $0 | – | -100,000 | -100.0% | -2.09% | – |
| IBB | Exit | ISHARES TRput | $0 | – | -250,000 | -100.0% | -4.88% | – |
| ITCI | Exit | INTRA CELLULAR THERAPIES INCput | $0 | – | -924,100 | -100.0% | -5.14% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 15 | Q2 2023 | 1.5% |
| OCULAR THERAPEUTIX INC | 15 | Q3 2023 | 1.4% |
| SAREPTA THERAPEUTICS INC | 14 | Q3 2023 | 6.4% |
| X4 PHARMACEUTICALS INC - PIPE | 14 | Q2 2023 | 1.4% |
| PROTARA THERAPEUTICS INC | 14 | Q3 2023 | 1.2% |
| SPDR SER TR | 13 | Q3 2023 | 9.0% |
| VAXCYTE INC | 13 | Q3 2023 | 2.9% |
| TRACON PHARMACEUTICALS INC | 13 | Q3 2023 | 1.4% |
| MILESTONE PHARMACEUTICALS IN | 13 | Q3 2023 | 1.7% |
| BELLUS HEALTH INC NEW | 13 | Q1 2023 | 1.8% |
View Ikarian Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 460,416 | 1.3% |
| X4 Pharmaceuticals, Inc | February 14, 2023 | 349,133 | 0.3% |
| aTYR PHARMA INC | February 14, 2022 | 35,048 | 0.1% |
| Cyclacel Pharmaceuticals, Inc. | February 14, 2022 | 99,422 | 1.0% |
| KalVista Pharmaceuticals, Inc. | February 14, 2022 | 36,576 | 0.2% |
| Lyra Therapeutics, Inc. | February 14, 2022 | 394,536 | 3.0% |
| Odonate Therapeutics, Inc. | February 14, 2022 | 1,340,631 | 3.5% |
| Protara Therapeutics, Inc. | February 14, 2022 | 279,256 | 2.5% |
| Science 37 Holdings, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| scPharmaceuticals Inc. | February 14, 2022 | 901,362 | 3.3% |
View Ikarian Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View Ikarian Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.